Market Place
Sourcing Support
Cadrenal Therapeutics Highlight EACTS Medical Congress Presentation
12 Nov 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Raises $4.7M from Warrants Exercise
01 Nov 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Raises $5.1 Million Via Market Facility
24 Oct 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Joins Corporate Of Anticoagulation Forum
23 Oct 2024 //
PR NEWSWIRE
Cadrenal To Join Lytham Partners Fall 2024 Investor Conference
23 Sep 2024 //
PR NEWSWIRE
Published Data Highlight Tecarfarin`s Potential For LVAD Patients
20 Aug 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
07 Aug 2024 //
PR NEWSWIRE
Cadrenal And Abbott Collaborate On Tecarfarin For LVAD Patients
06 Aug 2024 //
PR NEWSWIRE
Cadrenal Therapeutics To Present At Emerging Growth Conference
11 Jun 2024 //
PR NEWSWIRE
Cadrenal Highlights Anticoagulation Quality Data In LVAD Patients At ISHLT
03 Jun 2024 //
PR NEWSWIRE
Cadrenal Lytham May 30 Featured: Spring 2024 Investor Conference
23 May 2024 //
PR NEWSWIRE
Cadrenal At Noble Virtual Healthcare Conference On 4/18
11 Apr 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
11 Mar 2024 //
PR NEWSWIRE
Cadrenal Therapeutics to Participate at THT Conference
26 Feb 2024 //
PR NEWSWIRE
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer
08 Feb 2024 //
PR NEWSWIRE
Cadrenal Therapeutics to Present at the J.P. Morgan Annual Healthcare Conference
04 Jan 2024 //
PR NEWSWIRE
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics
19 Dec 2023 //
PR NEWSWIRE
Cadrenal Engages The Sage Group to Advance Tecarfarin`s Late-Stage Development
12 Dec 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
09 Nov 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist
05 Sep 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with APS
30 Aug 2023 //
PR NEWSWIRE
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Conference
28 Aug 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
10 Aug 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Expands Focus for Tecarfarin
01 Aug 2023 //
PR NEWSWIRE
Cadrenal Announces Appointment of Robert Lisicki to Board of Directors
24 Jul 2023 //
PR NEWSWIRE
Cadrenal Announces Closing of $7.5M Private Placement
14 Jul 2023 //
PR NEWSWIRE
Cadrenal to Participate in the 2023 BIO International Convention in Boston
01 Jun 2023 //
PR NEWSWIRE
Cadrenal Therapeutics to Participate in the Lytham Partners 2023 Conference
09 May 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Provides Fiscal Year 2022 Corporate Update
30 Mar 2023 //
PR NEWSWIRE
Cadrenal Recognizes National Kidney Month with Goal to Advance Tecarfarin
09 Mar 2023 //
PR NEWSWIRE
Cadrenal to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023
08 Feb 2023 //
PR NEWSWIRE
Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference
06 Feb 2023 //
PR NEWSWIRE
Cadrenal Therapeutics Announces Formation of Scientific Advisory Board
01 Feb 2023 //
PR NEWSWIRE
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
01 Jan 1970 //
PR NEWSWIRE
